(Q46115262)

19 December 2017

title

Phospholipase A2 inhibitors in atherosclerosis: the race is on. (English)

1 reference

19 December 2017

1 reference

Marshall A Corson

1

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

19 December 2017

published in

The Lancet

1 reference

19 December 2017

volume

373

1 reference

19 December 2017

issue

9664

1 reference

19 December 2017

page(s)

608-610

1 reference

19 December 2017

The phospholipase A2 superfamily and its group numbering system

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

Use of biomarkers to develop treatment strategies for atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

Role of secretory phospholipases in atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960378-0

7 January 2021

10.1016/S0140-6736(09)60378-0

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017